Cargando…

Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)

Recent randomized controlled multi-center trials JUPITER, CANTOS and COLCOT impressively demonstrated the effect of anti-inflammatory therapy on secondary prevention of cardiovascular events. These studies also rapidly re-vitalized the question of whether the C-reactive protein (CRP), the prototype...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaczkiewicz, Myron, Kostenzer, Katharina, Graf, Matthias, Mayer, Benjamin, Zimmermann, Oliver, Torzewski, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999566/
https://www.ncbi.nlm.nih.gov/pubmed/35407370
http://dx.doi.org/10.3390/jcm11071762
_version_ 1784685217132314624
author Zaczkiewicz, Myron
Kostenzer, Katharina
Graf, Matthias
Mayer, Benjamin
Zimmermann, Oliver
Torzewski, Jan
author_facet Zaczkiewicz, Myron
Kostenzer, Katharina
Graf, Matthias
Mayer, Benjamin
Zimmermann, Oliver
Torzewski, Jan
author_sort Zaczkiewicz, Myron
collection PubMed
description Recent randomized controlled multi-center trials JUPITER, CANTOS and COLCOT impressively demonstrated the effect of anti-inflammatory therapy on secondary prevention of cardiovascular events. These studies also rapidly re-vitalized the question of whether the C-reactive protein (CRP), the prototype human acute phase protein, is actively involved in atherosclerosis and its sequelae. Direct CRP inhibition may indeed improve the specificity and effectiveness of anti-inflammatory intervention. In the present paper, we report on the final results of our single-center C-reactive protein-Digoxin Observational Study (C-DOS). Methods and Results: Based on the experimental finding that cardiac glycosides potently inhibit hepatic CRP synthesis on the transcriptional level in vitro, 60 patients with decompensated heart failure, NYHA III–IV, severely reduced Left Ventricular Ejection Fraction (LVEF < 40%), and elevated CRP plasma levels were treated by either digoxin + conventional heart failure therapy (30 patients) or by conventional heart failure therapy alone (30 patients). Plasma CRP levels in both groups were assessed for 21 d. Plasma CRP levels on d1, d3 and d21 were compared by regression analysis. CRP levels d21–d1 significantly declined in both groups. Notably, comparative CRP reduction d21–d3 in digoxin versus the control group also revealed borderline significance (p = 0.051). Conclusions: This small observational trial provides the first piece of evidence that cardiac glycosides may inhibit CRP synthesis in humans. In case of further pharmacological developments, cardiac glycosides may emerge as lead compounds for chemical modification in order to improve the potency, selectivity and pharmacokinetics of CRP synthesis inhibition in cardiovascular disease.
format Online
Article
Text
id pubmed-8999566
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89995662022-04-12 Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS) Zaczkiewicz, Myron Kostenzer, Katharina Graf, Matthias Mayer, Benjamin Zimmermann, Oliver Torzewski, Jan J Clin Med Article Recent randomized controlled multi-center trials JUPITER, CANTOS and COLCOT impressively demonstrated the effect of anti-inflammatory therapy on secondary prevention of cardiovascular events. These studies also rapidly re-vitalized the question of whether the C-reactive protein (CRP), the prototype human acute phase protein, is actively involved in atherosclerosis and its sequelae. Direct CRP inhibition may indeed improve the specificity and effectiveness of anti-inflammatory intervention. In the present paper, we report on the final results of our single-center C-reactive protein-Digoxin Observational Study (C-DOS). Methods and Results: Based on the experimental finding that cardiac glycosides potently inhibit hepatic CRP synthesis on the transcriptional level in vitro, 60 patients with decompensated heart failure, NYHA III–IV, severely reduced Left Ventricular Ejection Fraction (LVEF < 40%), and elevated CRP plasma levels were treated by either digoxin + conventional heart failure therapy (30 patients) or by conventional heart failure therapy alone (30 patients). Plasma CRP levels in both groups were assessed for 21 d. Plasma CRP levels on d1, d3 and d21 were compared by regression analysis. CRP levels d21–d1 significantly declined in both groups. Notably, comparative CRP reduction d21–d3 in digoxin versus the control group also revealed borderline significance (p = 0.051). Conclusions: This small observational trial provides the first piece of evidence that cardiac glycosides may inhibit CRP synthesis in humans. In case of further pharmacological developments, cardiac glycosides may emerge as lead compounds for chemical modification in order to improve the potency, selectivity and pharmacokinetics of CRP synthesis inhibition in cardiovascular disease. MDPI 2022-03-22 /pmc/articles/PMC8999566/ /pubmed/35407370 http://dx.doi.org/10.3390/jcm11071762 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zaczkiewicz, Myron
Kostenzer, Katharina
Graf, Matthias
Mayer, Benjamin
Zimmermann, Oliver
Torzewski, Jan
Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)
title Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)
title_full Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)
title_fullStr Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)
title_full_unstemmed Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)
title_short Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS)
title_sort cardiac glycosides lower c-reactive protein plasma levels in patients with decompensated heart failure: results from the single-center c-reactive protein-digoxin observational study (c-dos)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999566/
https://www.ncbi.nlm.nih.gov/pubmed/35407370
http://dx.doi.org/10.3390/jcm11071762
work_keys_str_mv AT zaczkiewiczmyron cardiacglycosideslowercreactiveproteinplasmalevelsinpatientswithdecompensatedheartfailureresultsfromthesinglecentercreactiveproteindigoxinobservationalstudycdos
AT kostenzerkatharina cardiacglycosideslowercreactiveproteinplasmalevelsinpatientswithdecompensatedheartfailureresultsfromthesinglecentercreactiveproteindigoxinobservationalstudycdos
AT grafmatthias cardiacglycosideslowercreactiveproteinplasmalevelsinpatientswithdecompensatedheartfailureresultsfromthesinglecentercreactiveproteindigoxinobservationalstudycdos
AT mayerbenjamin cardiacglycosideslowercreactiveproteinplasmalevelsinpatientswithdecompensatedheartfailureresultsfromthesinglecentercreactiveproteindigoxinobservationalstudycdos
AT zimmermannoliver cardiacglycosideslowercreactiveproteinplasmalevelsinpatientswithdecompensatedheartfailureresultsfromthesinglecentercreactiveproteindigoxinobservationalstudycdos
AT torzewskijan cardiacglycosideslowercreactiveproteinplasmalevelsinpatientswithdecompensatedheartfailureresultsfromthesinglecentercreactiveproteindigoxinobservationalstudycdos